Revisiting the TMAP Scandal: J&J Paid Allen Frances to Develop Schizophrenia Guideline

4
251

In a commentary published in the University of Ottawa nursing journal Aporia, Paula Caplan writes about how Allen Frances and two other academic psychiatrists were paid by Johnson & Johnson in the late 1990s to write a practice guideline that identified Risperdal, the company’s new atypical antipsychotic, as a preferred treatment for schizophrenia.

This fact was first revealed in a 2010 report by David Rothman, who was hired as an expert witness by the state of Texas when it sued J&J for Medicaid fraud in its marketing of Risperdal. Frances, who directed the task force that authored DSM-IV, has written a response to Caplan’s article on Huffington Post.

Caplan, Paula. Diagnosisgate: Conflict of Interest at the Top of the Psychiatric Apparatus. Aporia. Volume 7, Issue 1. (Full text)

‘Diagnosisgate’ Deconstructed and Debunked (The Huffington Post, March 6, 2015)

Expert Witness Report – David J. Rothman, October 15, 2010 (Distributed on 1boringoldman.com)

Support MIA

MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.

$
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Billing Details

Donation Total: $20

4 COMMENTS

  1. How long will we tolerate bribing of doctors by pharma? You should not allow corporations to regulate themselves and buying people who are supposed to check if you’re not poisoning patients instead of helping them is just that. Pharma being in control of clinical trails is a blatant conflict of interest.

  2. Great article Rob! Recovery for schizophrenics is definitely possible. Personally, I like the mental health recovery writings of Will Jiang, in particular. His autobiography A Schizophrenic Will: A Story of Madness, A Story of Hope is inspriational, as is his book Guide to Natural Mental Health: Anxiety, Bipolar, Depression, Schizophrenia, and Digital Addiction: Nutrition and Complementary Therapies. His author page is located at http://www.mentalhealthbooks.net. And, it turns out, he is quite an accomplished designer. His web design company is located online at http://www.newyorkwebdesign.nyc . It is hard to believe this man suffers from schizophrenia.

  3. Paula,

    Thank you for pointing out that the upper echelon of the psychiatric industry was involved in the psycho / pharmaceutical industries fraud and propaganda programs that have seemingly usurped the entire medical industry, and distorted the viewpoints of most Americans, now.

    And I believe it’s important for people to understand the actual possible effects of Risperdal. And I agree there was an insane desire, on the parts of the psychiatrists, to prescribe Risperdal to healthy patients who presented with concerns of child abuse, in 2001.

    A child’s dose of Risperdal, .5 mg, can make a grown healthy adult who presented with concerns of real life problems become psychotic within two weeks, via the central symptoms of neuroleptic induced anticholinergic intoxication syndrome.

    “Agents with anticholinergic properties (e.g. … neuroleptics …) … may result in … the anticholinergic intoxication syndrome … Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.”

    The central symptoms of neuroleptic induced anticholinergic intoxication syndrome are almost identical to today’s symptoms of schizophrenia. The neuroleptic drugs do cause the schizophrenia symptoms.

    It is probable that the most common etiology of “schizophrenia” is neuroleptic induced anticholinergic intoxication syndrome.

    .5 mg is not a safe dose of Risperdal for any child, and it’s not a safe dose for even some adults.